Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2019 07:00 ET | Source: Aravive, Inc.

Aravive to Host Key Opinion Leader Breakfast Symposium on AVB-S6-500 and the GAS6-AXL Pathway on February 5, 2019

HOUSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) symposium focused on...
December 11, 2018 08:05 ET | Source: Aravive, Inc.

Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer

HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun treating patients in the Phase 1b...
November 26, 2018 07:00 ET | Source: Aravive, Inc.

Aravive Announces Participation at Upcoming Investor Conference

HOUSTON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that company management will participate at the following...
November 13, 2018 07:00 ET | Source: Aravive, Inc.

Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium

HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced detailed results of its first-in-human Phase 1 clinical trial of...
November 06, 2018 16:05 ET | Source: Aravive, Inc.

Aravive Reports Third Quarter 2018 Financial Results and Provides Company Updates

- Merger completed; now operating as Aravive, Inc. (Nasdaq:ARAV), a clinical-stage biopharmaceutical company advancing innovative oncology therapeutics - FDA Fast Track designation granted...
October 15, 2018 07:00 ET | Source: Versartis, Inc.

Aravive Biologics and Versartis Complete Merger

The combined company, Aravive, Inc., to trade on Nasdaq under ticker symbol “ARAV” beginning October 16, 2018, concurrent with a 1-for-6 reverse split of common shares HOUSTON, Oct. 15, 2018 (GLOBE...
August 07, 2018 16:15 ET | Source: Versartis, Inc.

Versartis Reports Second Quarter 2018 Financial Results and Reviews Recent Developments

MENLO PARK, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR) today announced financial results for the second quarter ended June 30, 2018 and provided a review of recent...
June 04, 2018 08:00 ET | Source: Versartis, Inc.

Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics

- Tolerability and proof-of-mechanism for lead candidate AVB-S6-500, a novel GAS6-AXL pathway inhibitor, established in ongoing Phase 1 clinical study - Multi-study clinical development program in...
May 08, 2018 16:15 ET | Source: Versartis, Inc.

Versartis Reports First Quarter 2018 Financial Results

MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended...
March 01, 2018 16:05 ET | Source: Versartis, Inc.

Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

MENLO PARK, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the fourth quarter and...